Cargando…
Cost-effectiveness analysis of introducing HTLV-1 testing in South Africa
Autores principales: | Sykes, Wendy, Coleman, Charl, Beck, Genevieve, Mhlanga, Jabu, Hlela, Carol, Custer, Brian, Murphy, Edward L, Vermeulen, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578686/ http://dx.doi.org/10.1186/1742-4690-12-S1-P81 |
Ejemplares similares
-
Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021.
por: Sykes, Wendy, et al.
Publicado: (2021) -
Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in eight provinces of South Africa in November 2021
por: Cable, Russel, et al.
Publicado: (2022) -
Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa in March 2022
por: Bingham, Jeremy, et al.
Publicado: (2022) -
Human T-lymphotropic virus type 1(HTLV-1) integration, HTLV-1-associated infective dermatitis (IDH) and the risk of Adult T cell leukaemia/lymphoma (ATLL)
por: Hlela, Carol, et al.
Publicado: (2011) -
Cost-Effectiveness of Introducing the SILCS Diaphragm in South Africa
por: Lépine, Aurélia, et al.
Publicado: (2015)